Marios K. Georgakis

The paper identifies a hypervascular, BBB-compromised state in aging mice linked to cognitive decline and shows pharmacological stabilization improves vascular and cognitive outcomes.

AGT variants mimicking hepatic angiotensinogen synthesis inhibition are linked, via drug-target Mendelian randomization, to lower coronary artery disease, stroke and heart failure risk and higher potassium.

This study identifies a genetic association between thromboembolism risk and long COVID in individuals of European ancestry, suggesting thromboembolism as a potential contributor to long COVID pathogenesis.

This study identifies genetic variants associated with circulating cytokine levels and suggests potential drug targets for immune-related diseases.

The paper performs deep resequencing of the 1q22 locus in non-lobar ICH cases and controls to identify causal variants and mechanisms.

The paper uses proteogenomic integration to identify CXCL10 as a mediator of IL-6 signaling effects on atherosclerosis, showing its association with cardiovascular disease risk and lesion characteristics.

This paper develops a genomic risk score for intracerebral hemorrhage using genome-wide association data and validates its predictive power in multiple cohorts.

This study uses Mendelian Randomization to show that a higher genetic response to statins is linked to increased intracerebral hemorrhage risk among statin users.

The paper identifies rare variants in HTRA1 and its substrate EGFL8 associated with increased white matter hyperintensities using whole-exome sequencing data from 16,511 UK Biobank individuals.

This study uses Mendelian randomization to assess the causal effects of education, smoking, and BMI on stroke risk, finding independent associations with different stroke subtypes.

This study uses Mendelian randomization to show that genetic predisposition to T2D and hyperglycemia increases risk of ischemic and small vessel stroke, with distinct effects of insulin resistance and beta-cell dysfunction.

The paper uses genetic variants to investigate side effects and repurposing potential of antihypertensive drugs, finding a link between calcium channel blockers and increased diverticulosis risk.